%20Co.%2C%20Ltd./other/PharmaResources_Shanghai_Co._Ltd.-logo.png)
PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings
PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 北京市嘉源律师事务所关于上海泓博智源医药股份有限公司2025年年度股东会的法律意见书 | 2026-05-19 | Chinese | |
| 2025年年度股东会决议公告 | 2026-05-19 | Chinese | |
| 中信证券股份有限公司关于上海泓博智源医药股份有限公司2025年度持续督导定期现场检查报告 | 2026-05-18 | Chinese | |
| 中信证券股份有限公司关于上海泓博智源医药股份有限公司2025年度持续督导培训情况的报告 | 2026-05-18 | Chinese | |
| 中信证券股份有限公司关于上海泓博智源医药股份有限公司持续督导保荐总结报告书 | 2026-05-18 | Chinese | |
| 中信证券股份有限公司关于上海泓博智源医药股份有限公司2025年度跟踪报告 | 2026-05-18 | Chinese |
Browse filings by year
5 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46534700 | 北京市嘉源律师事务所关于上海泓博智源医药股份有限公司2025年年度股东会的法律意见书 | 2026-05-19 | Chinese | ||
| 46534704 | 2025年年度股东会决议公告 | 2026-05-19 | Chinese | ||
| 46384983 | 中信证券股份有限公司关于上海泓博智源医药股份有限公司2025年度持续督导定期现场检查报告 | 2026-05-18 | Chinese | ||
| 46384981 | 中信证券股份有限公司关于上海泓博智源医药股份有限公司2025年度持续督导培训情况的报告 | 2026-05-18 | Chinese | ||
| 46384980 | 中信证券股份有限公司关于上海泓博智源医药股份有限公司持续督导保荐总结报告书 | 2026-05-18 | Chinese | ||
| 46384979 | 中信证券股份有限公司关于上海泓博智源医药股份有限公司2025年度跟踪报告 | 2026-05-18 | Chinese | ||
| 46350313 | 关于举行2025年度网上业绩说明会的公告 | 2026-05-15 | Chinese | ||
| 40012741 | 第四届董事会第七次会议决议公告 | 2026-04-28 | Chinese | ||
| 40012736 | 2024年限制性股票激励计划授予价格调整、第一个归属期归属条件成就及部分限制性股票作废相关事项的法律意见书 | 2026-04-28 | Chinese | ||
| 40012727 | 2026年一季度报告 | 2026-04-28 | Chinese | ||
| 40012714 | 2025年年度审计报告 | 2026-04-28 | Chinese | ||
| 40012695 | 2025年年度报告摘要 | 2026-04-28 | Chinese | ||
| 40012688 | 关于调整2024年限制性股票激励计划授予价格的公告 | 2026-04-28 | Chinese | ||
| 40012683 | 2025年度董事会工作报告 | 2026-04-28 | Chinese | ||
| 40012671 | 2025年度独立董事述职报告 (尤启冬) | 2026-04-28 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
ACROBIOSYSTEMS CO.,LTD.
Provides recombinant proteins and reagents for life science…
|
301080 | CN | Professional, scientific and te… |
|
ACTINOGEN MEDICAL LIMITED
Developing cortisol-inhibiting therapies for Alzheimer's an…
|
ACW | AU | Professional, scientific and te… |
|
Active Biotech
Biotechnology company developing drugs for oncology and inf…
|
ACTI | SE | Professional, scientific and te… |
|
Adagene Inc.
Clinical-stage biotech developing antibody-based immunother…
|
ADAG | KY | Professional, scientific and te… |
|
ADALTA LIMITED
Clinical-stage biotech developing i-body protein therapeuti…
|
1AD | AU | Professional, scientific and te… |
|
Adaptive Biotechnologies Corp
Decodes the adaptive immune system to develop products for …
|
ADPT | US | Professional, scientific and te… |
|
Adeia Inc.
R&D company that licenses IP for the media, entertainment, …
|
ADEA | US | Professional, scientific and te… |
|
Aditxt, Inc.
Acquires, develops, and deploys health technologies to addr…
|
ADTX | US | Professional, scientific and te… |
|
Advanced Biomed Inc.
Develops microfluidic biochip diagnostic systems for precis…
|
ADVB | US | Professional, scientific and te… |
|
Advanced Proteome Therapeutics Corporation
Develops proprietary technology for chemical modification o…
|
APC.H | CA | Professional, scientific and te… |
PharmaResources (Shanghai) Co., Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56163/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56163 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56163 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56163 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56163}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for PharmaResources (Shanghai) Co., Ltd. (id: 56163)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.